ChemoCentryxs

ChemoCentryx was a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small molecule therapeutics. The company's primary area of research and development was in targeting chemokine receptors and their ligands, which play a role in inflammatory diseases and cancer. Their lead drug, TAVNEOS (avacopan), was approved by the U.S. Food and Drug Administration (FDA) in October 2021 for the treatment of adult patients with severe active ANCA-associated vasculitis. ANCA-associated vasculitis is a rare autoimmune disease that can cause inflammation of small blood vessels.

The development of TAVNEOS represented a significant milestone for ChemoCentryx, as it was their first drug to receive regulatory approval. The company also had a pipeline of other drug candidates in various stages of clinical development, exploring potential treatments for other inflammatory and autoimmune conditions, as well as certain types of cancer. ChemoCentryx was founded in 1997 and was headquartered in San Carlos, California. In October 2022, Amgen completed its acquisition of ChemoCentryx. This acquisition aimed to integrate ChemoCentryx's expertise and pipeline, particularly avacopan, into Amgen's broader inflammation and nephrology portfolio. The company operated as a subsidiary of Amgen following the acquisition.